glutathione and triple negative breast cancer

glutathione and triple negative breast cancer GSTP1 Is a Driver of Triple-Negative Cell Metabolism Pathogenicity Glutathione-Disrupting Nanotherapeutics Potentiate Ferroptosis for

Name: glutathione and triple negative breast cancer GSTP1 Is a Driver of Triple-Negative Cell Metabolism Pathogenicity Glutathione-Disrupting Nanotherapeutics Potentiate Ferroptosis for
Brand: crisbcreativa.com
SKU: 58106076572
Price: 25.44 USD
Availability: InStock
Rating: 4.478800000000001 (16 reviews)

Glutathione Disrupting Nanotherapeutics Potentiate Ferroptosis for Treating Luminal Androgen Receptor Positive Triple Negative Breast Cancer ACS Nano Mitochondrial Redox Vulnerabilities in Triple Negative Breast Cancer: Integrative Perspectives and Emerging Therapeutic Strategies glutathione autophagy Regulatory network of ferroptosis and by targeting oxidative stress defense using sulfasalazine in triple negative breast cancer Apoptosis and glutathione: beyond an Heterogeneity and transcriptional drivers of triple negative breast cancer: Cell Reports Glutathione depletion and dihydroorotate dehydrogenase inhibition actuated ferroptosis augment to surmount triple negative breast cancer ScienceDirect

SKU: 58106076572 · From crisbcreativa.com

4.5

USD25.44 USD58.44

Pay in 4 interest-free payments of $6.36 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 2 - Aug 7

Description

The largest increases were observed in Taiwan (Province of China) (EAPC = 3.60, 95% CI: 2.84 to 4.35), Zimbabwe (EAPC = 3.34, 95% CI: 2.52 to 4.16), and Niue (EAPC = 3.04, 95% CI: 2.58 to 3.50), while the most significant declines were recorded in the Grand Duchy of Luxembourg (EAPC = 2.96, 95% CI: 3.07 to 2.85), Tuvalu (EAPC = 2.57, 95% CI: 2.65 to 2.49), and the Republic of Haiti (EAPC = 2.56, 95% CI: 2.74 to 2.38)

J Enzyme Inhib Med Chem 30(2):264269 eker Karatoprak G, Dumlupnar B, Celep E, Kurt Celep I, Kpeli Akkol E, Sobarzo-Snchez E (2024) A comprehensive review on the potential of coumarin and related derivatives as multi-target therapeutic agents in the management of gynecological cancers